Your browser doesn't support javascript.
loading
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma.
Li, Qiang; Wang, Xiaolan; Li, Deju; Liu, Yulong; Liu, Kangshou; Liang, Junjie; Sun, Jian; Jiang, Quan; Li, Jiexing; Liu, Zhilong; Gong, Jian; Xiang, Leyang; Jia, Zhidong; Chen, Zhiwei; Cao, Mingrong; Jiang, Yuchuan.
Afiliación
  • Li Q; Department of Hepatobiliary Surgery, The First Affiliated Hospital, Jinan University.
  • Wang X; Department of Hepatobiliary Surgery, The First Affiliated Hospital, Jinan University; Dongpu Branch, The First Affiliated Hospital, Jinan University.
  • Li D; Department of Hepatobiliary Surgery, The First Affiliated Hospital, Jinan University.
  • Liu Y; Department of Vascular Intervention, The First Affiliated Hospital, Jinan University.
  • Liu K; Department of Hepatobiliary Surgery, The First Affiliated Hospital, Jinan University.
  • Liang J; Department of Hepatobiliary Surgery, The First Affiliated Hospital, Jinan University.
  • Sun J; Department of Hepatobiliary Surgery, The First Affiliated Hospital, Jinan University.
  • Jiang Q; Department of Hepatobiliary Surgery, The First Affiliated Hospital, Jinan University.
  • Li J; Department of Hepatobiliary Surgery, The First Affiliated Hospital, Jinan University.
  • Liu Z; Department of Hepatobiliary Surgery, The First Affiliated Hospital, Jinan University.
  • Gong J; Department of Nuclear Medicine, The First Affiliated Hospital, Jinan University.
  • Xiang L; Department of Hepatobiliary Surgery, The First Affiliated Hospital, Jinan University.
  • Jia Z; Department of Hepatobiliary Surgery, The First Affiliated Hospital, Jinan University.
  • Chen Z; Department of Hepatobiliary Surgery, The First Affiliated Hospital, Jinan University.
  • Cao M; Department of Hepatobiliary Surgery, The First Affiliated Hospital, Jinan University; tcaomr@jnu.edu.cn.
  • Jiang Y; Department of Hepatobiliary Surgery, The First Affiliated Hospital, Jinan University; Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University; Jiangych17@outlook.com.
J Vis Exp ; (207)2024 May 24.
Article en En | MEDLINE | ID: mdl-38856215
ABSTRACT
This study showcases a comprehensive treatment protocol for high-risk hepatocellular carcinoma (HCC) patients, focusing on the combined use of Y-90 transarterial radioembolization (TARE) and Programmed Cell Death-1 (PD-1) inhibitors as neoadjuvant therapy. Highlighted through a case report, it offers a step-by-step reference for similar therapeutic interventions. A retrospective analysis was conducted on a patient who underwent hepatectomy following Y-90 TARE and PD-1 inhibitor treatment. Key demographic and clinical details were recorded at admission to guide therapy selection. Y-90 TARE suitability and dosage calculation were based on Technetium-99m (Tc-99m) macroaggregated albumin (MAA) perfusion mapping tests. Lesion coverage by Y-90 microspheres was confirmed through single photon emission computed tomography/computed tomography (SPECT/CT) fusion imaging, and adverse reactions and follow-up outcomes were meticulously documented. The patient, with a 7.2 cm HCC in the right hepatic lobe (T1bN0M0, BCLC A, CNLC Ib) and an initial alpha-fetoprotein (AFP) level of 66,840 ng/mL, opted for Y-90 TARE due to high recurrence risk and initial surgery refusal. The therapy's parameters, including the lung shunting fraction (LSF) and non-tumor ratio (TNR), were within therapeutic limits. A total of 1.36 GBq Y-90 was administered. At 1 month post-therapy, the tumor shrank to 6 cm with partial necrosis, and AFP levels dropped to 21,155 ng/mL, remaining stable for 3 months. After 3 months, PD-1 inhibitor treatment led to further tumor reduction to 4 cm and AFP decrease to 1.84 ng/mL. The patient then underwent hepatectomy; histopathology confirmed complete tumor necrosis. At 12 months post-surgery, no tumor recurrence or metastasis was observed in follow-up sessions. This protocol demonstrates the effective combination of Y-90 TARE and PD-1 inhibitor as a bridging strategy to surgery for HCC patients at high recurrence risk, providing a practical guide for implementing this approach.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Radioisótopos de Itrio / Carcinoma Hepatocelular / Terapia Neoadyuvante / Embolización Terapéutica / Neoplasias Hepáticas Idioma: En Revista: J Vis Exp Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Radioisótopos de Itrio / Carcinoma Hepatocelular / Terapia Neoadyuvante / Embolización Terapéutica / Neoplasias Hepáticas Idioma: En Revista: J Vis Exp Año: 2024 Tipo del documento: Article